About
NEC Bio B.V. develops groundbreaking therapies for patients globally using advanced AI technologies, focusing on personalized cancer vaccines and next-generation vaccines for infectious diseases. Their core approach involves identifying patient-specific neoantigens for oncology and highly immunogenic antigens for infectious diseases, leveraging proprietary AI/ML technologies like NEC Immune Profiler and NEC B-cell Epitope Predictor. They serve patients with indications including ovarian cancer, head and neck cancer, betacoronaviruses, and tropical diseases.
Technology stack
detected 2026-06-19Est. monthly stack spend~$70/mo
Email
Proofpoint
gateway-fronted
Comments
No comments yet. Be the first to share your take.
Frequently asked
What does OncoImmunity do?
NEC Bio B.V. develops groundbreaking therapies for patients globally using advanced AI technologies, focusing on personalized cancer vaccines and next-generation vaccines for infectious diseases. Their core approach involves identifying patient-specific neoantigens for oncology and highly immunogenic antigens for infectious diseases, leveraging proprietary AI/ML technologies like NEC Immune Profiler and NEC B-cell Epitope Predictor. They serve patients with indications including ovarian cancer,…
How much funding has OncoImmunity raised?
OncoImmunity has raised a total of $5M in funding. The most recent round on record is Seed.
Where is OncoImmunity headquartered?
OncoImmunity is headquartered in Oslo, Norway.
When was OncoImmunity founded?
OncoImmunity was founded in 2014.